Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Acute effects of ayahuasca in a juvenile non-human primate model of depression.

da Silva FS, Silva EAS, Sousa GM Jr, Maia-de-Oliveira JP, Soares-Rachetti VP, de Araujo DB, Sousa MBC, Lobão-Soares B, Hallak J, Galvão-Coelho NL.

Braz J Psychiatry. 2018 Nov 8:0. doi: 10.1590/1516-4446-2018-0140. [Epub ahead of print]

2.

Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial.

Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, Mota-Rolim SA, Osório FL, Sanches R, Dos Santos RG, Tófoli LF, de Oliveira Silveira G, Yonamine M, Riba J, Santos FR, Silva-Junior AA, Alchieri JC, Galvão-Coelho NL, Lobão-Soares B, Hallak JEC, Arcoverde E, Maia-de-Oliveira JP, Araújo DB.

Psychol Med. 2019 Mar;49(4):655-663. doi: 10.1017/S0033291718001356. Epub 2018 Jun 15.

3.

Cortisol Modulation by Ayahuasca in Patients With Treatment Resistant Depression and Healthy Controls.

Galvão ACM, de Almeida RN, Silva EADS, Freire FAM, Palhano-Fontes F, Onias H, Arcoverde E, Maia-de-Oliveira JP, de Araújo DB, Lobão-Soares B, Galvão-Coelho NL.

Front Psychiatry. 2018 May 8;9:185. doi: 10.3389/fpsyt.2018.00185. eCollection 2018.

4.

An Overview of Animal Models Related to Schizophrenia.

Winship IR, Dursun SM, Baker GB, Balista PA, Kandratavicius L, Maia-de-Oliveira JP, Hallak J, Howland JG.

Can J Psychiatry. 2019 Jan;64(1):5-17. doi: 10.1177/0706743718773728. Epub 2018 May 9.

PMID:
29742910
5.

Letter to the Editor: Sodium nitroprusside for schizophrenia: could methodological variables account for the different results obtained?

Maia-de-Oliveira JP, Baker GB, Dursun SM, Hallak JE.

Psychol Med. 2017 Apr;47(5):981-982. doi: 10.1017/S003329171600307X. Epub 2016 Dec 9. No abstract available.

PMID:
27931266
6.

Nitric Oxide's Involvement in the Spectrum of Psychotic Disorders.

Maia-de-Oliveira JP, Kandratavicius L, Nunes EA, Machado-de-Sousa JP, Hallak JE, Dursun SM.

Curr Med Chem. 2016;23(24):2680-2691. Review.

PMID:
27450675
7.

Role of Methylene Blue in Trauma Neuroprotection and Neuropsychiatric Diseases.

Batista-Filho MM, Kandratavicius L, Nunes EA, Tumas V, Colli BO, Hallak JE, Maia-de-Oliveira JP, Evora PR.

CNS Neurol Disord Drug Targets. 2016;15(8):976-986. Review.

PMID:
27450870
8.

Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study.

Sanches RF, de Lima Osório F, Dos Santos RG, Macedo LR, Maia-de-Oliveira JP, Wichert-Ana L, de Araujo DB, Riba J, Crippa JA, Hallak JE.

J Clin Psychopharmacol. 2016 Feb;36(1):77-81. doi: 10.1097/JCP.0000000000000436.

PMID:
26650973
9.

Cognition in at-risk mental states for psychosis.

de Paula AL, Hallak JE, Maia-de-Oliveira JP, Bressan RA, Machado-de-Sousa JP.

Neurosci Biobehav Rev. 2015 Oct;57:199-208. doi: 10.1016/j.neubiorev.2015.09.006. Epub 2015 Sep 10. Review.

PMID:
26365107
10.

Psychotic syndrome secondary to meningioma treated with a low dose of olanzapine.

Maia-de-Oliveira JP, Brasileiro LE, Correia CE, Machado-de-Sousa JP, Hallak JE.

Braz J Psychiatry. 2015 Apr-Jun;37(2):179-80. doi: 10.1590/1516-4446-2014-1550. Epub 2015 Apr 1. No abstract available.

11.

Effects of nitric oxide-related compounds in the acute ketamine animal model of schizophrenia.

Kandratavicius L, Balista PA, Wolf DC, Abrao J, Evora PR, Rodrigues AJ, Chaves C, Maia-de-Oliveira JP, Leite JP, Dursun SM, Baker GB, Guimaraes FS, Hallak JE.

BMC Neurosci. 2015 Mar 7;16:9. doi: 10.1186/s12868-015-0149-3.

12.

Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report.

Osório Fde L, Sanches RF, Macedo LR, Santos RG, Maia-de-Oliveira JP, Wichert-Ana L, Araujo DB, Riba J, Crippa JA, Hallak JE.

Braz J Psychiatry. 2015 Jan-Mar;37(1):13-20. doi: 10.1590/1516-4446-2014-1496.

13.

Paliperidone palmitate for refractory and clozapine-resistant schizophrenia.

Maia-de-Oliveira JP, Nunes EA, Ushirohira JM, Machado-de-Sousa JP, Bressan RA, Hallak JE.

J Neuropsychiatry Clin Neurosci. 2015 Winter;27(1):e14-6. doi: 10.1176/appi.neuropsych.13120374. Epub 2014 Dec 12.

PMID:
25716490
14.

Nitroprusside single-dose prevents the psychosis-like behavior induced by ketamine in rats for up to one week.

Maia-de-Oliveira JP, Lobão-Soares B, Ramalho T, Gavioli EC, Soares VP, Teixeira L, Baker GB, Dursun SM, Hallak JE.

Schizophr Res. 2015 Mar;162(1-3):211-5. doi: 10.1016/j.schres.2014.12.035. Epub 2015 Jan 10.

PMID:
25586741
15.

The effects of sodium nitroprusside treatment on cognitive deficits in schizophrenia: a pilot study.

Maia-de-Oliveira JP, Abrao J, Evora PR, Zuardi AW, Crippa JA, Belmonte-de-Abreu P, Baker GB, Dursun SM, Hallak JE.

J Clin Psychopharmacol. 2015 Feb;35(1):83-5. doi: 10.1097/JCP.0000000000000258. No abstract available.

PMID:
25502490
16.

Effects of minocycline add-on treatment on brain morphometry and cerebral perfusion in recent-onset schizophrenia.

Chaves C, Marque CR, Maia-de-Oliveira JP, Wichert-Ana L, Ferrari TB, Santos AC, Araújo D, Machado-de-Sousa JP, Bressan RA, Elkis H, Crippa JA, Guimarães FS, Zuardi AW, Baker GB, Dursun SM, Hallak JE.

Schizophr Res. 2015 Feb;161(2-3):439-45. doi: 10.1016/j.schres.2014.11.031. Epub 2014 Dec 12.

PMID:
25497439
17.

Sodium nitroprusside, a nitric oxide donor for novel treatment of schizophrenia, may also modulate dopaminergic systems.

Maia-de-Oliveira JP, Lobão-Soares B, Baker GB, Dursun SM, Hallak JE.

Schizophr Res. 2014 Nov;159(2-3):558-9. doi: 10.1016/j.schres.2014.08.020. Epub 2014 Sep 13. No abstract available.

PMID:
25223842
18.

Sodium nitroprusside treatment of clozapine-refractory schizophrenia.

Maia-de-Oliveira JP, Belmonte-de-Abreu P, Bressan RA, Cachoeira C, Baker GB, Dursun SM, Hallak JE.

J Clin Psychopharmacol. 2014 Dec;34(6):761-3. doi: 10.1097/JCP.0000000000000217. No abstract available.

PMID:
25203464
19.

Why we should use long-acting injectable antipsychotics more frequently.

Maia-de-Oliveira JP, Bressan RA, Elkis H, Machado-de-Sousa JP, Hallak JE.

Braz J Psychiatry. 2013 Jul-Sep;35(3):217-8. doi: 10.1590/1516-4446-2013-3503. No abstract available.

20.

Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial.

Hallak JE, Maia-de-Oliveira JP, Abrao J, Evora PR, Zuardi AW, Crippa JA, Belmonte-de-Abreu P, Baker GB, Dursun SM.

JAMA Psychiatry. 2013 Jul;70(7):668-76. doi: 10.1001/jamapsychiatry.2013.1292.

PMID:
23699763
21.

Nitric oxide plasma/serum levels in patients with schizophrenia: a systematic review and meta-analysis.

Maia-de-Oliveira JP, Trzesniak C, Oliveira IR, Kempton MJ, Rezende TM, Iego S, Baker GB, Dursun SM, Machado-de-Sousa JP, Hallak JE.

Braz J Psychiatry. 2012 Oct;34 Suppl 2:S149-55. Review. English, Portuguese.

22.

A false case of clozapine-resistant schizophrenia.

Maia-de-Oliveira JP, Pinto JP, Alexandre V, Machado-de-Sousa JP, Morais SL, Chaves C, Sakamoto AC, Zuardi AW, Crippa JA, Hallak JE.

Case Rep Med. 2010;2010:534027. doi: 10.1155/2010/534027. Epub 2010 Mar 11.

23.

Functional neuroimaging of minocycline's effect in a patient with schizophrenia.

Chaves C, de Marque CR, Wichert-Ana L, Maia-de-Oliveira JP, Itikawa EN, Crippa JA, Zuardi AW, Todd KG, Baker GB, Dursun SM, Hallak JE.

Prog Neuropsychopharmacol Biol Psychiatry. 2010 Apr 16;34(3):550-2. doi: 10.1016/j.pnpbp.2010.01.020. Epub 2010 Feb 6. No abstract available.

PMID:
20138948

Supplemental Content

Loading ...
Support Center